on MAUNA KEA TECHNOLOGIES (EPA:MKEA)
Mauna Kea Technologies expands the use of Cellvizio® for the detection of pancreatic cysts
Mauna Kea Technologies announces the international rollout of its Cellvizio® technology for the early detection of pancreatic cysts, marking a significant medical milestone. In Spain, the Centro Médico Teknon in Barcelona, and in the United Arab Emirates, King's College Hospital in Dubai, have recently adopted this innovative technology. Cellvizio® achieves 96% accuracy in differentiating pancreatic cysts, thereby reducing unnecessary surgeries by more than 40%.
Pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate of less than 10%. This technological advancement could improve early diagnosis and personalize treatments for many patients worldwide.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAUNA KEA TECHNOLOGIES news